717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials

BACKGROUND: In the United States, CABP is the second most common cause of hospitalization and a leading cause of infectious death. Patients with chronic obstructive pulmonary disease (COPD)/asthma or diabetes are at risk for CABP and associated mortality. Similarly, patients with underlying cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Schranz, Jennifer, Goldberg, Lisa, Das, Anita F, Alexander, Elizabeth, Moran, Gregory J, Sandrock, Christian, Shorr, Andrew F, Gelone, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811254/
http://dx.doi.org/10.1093/ofid/ofz360.785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811254/
http://dx.doi.org/10.1093/ofid/ofz360.785

Ejemplares similares